Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer.

ABSTRACT:

Background

Testosterone level of < 50 ng/dL has been used to define castrate level after surgery or after androgen deprivation treatment (ADT) in metastatic prostate cancer (PC).

Aim

To evaluate the effect of two different castrate testosterone levels, < 50 and < 20 ng/dL, on biochemical relapse free survival (BRFS) in patients with non-metastatic intermediate and high risk PC receiving definitive radiotherapy (RT) and ADT.

Methods

Between April 1998 and February 2011; 173 patients with intermediate and high risk disease were treated. Radiotherapy was delivered by either three-dimensional-conformal technique to a total dose of 73.4 Gy at the ICRU reference point or intensity modulated radiotherapy technique to a total dose of 76 Gy. All the patients received 3 mo of n

SUBMITTER: Ozyigit G 

PROVIDER: S-EPMC6717705 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature